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We previously reported that selected mutations of highly conserved arginine residues within the LLP regions of HIV-1ME46 gp41 had diverse
effects on Env function. In the current study, we sought to test if the observed LLP mutant phenotypes would be similar in HIV-189.6. The results
of the current studies revealed that the LLP-1 mutations conferred reduced Env incorporation, infectivity, and replication phenotypes in both
viruses, while homologous LLP-2 mutations had differential phenotypical effects between the two strains. In particular, several of the 89.6 LLP-2
mutant viruses were replication defective in CEMX174 cells despite having increased levels of Env incorporation, and with both strains, there
were differential effects on infectivity. This comparison of homologous point mutations in two different strains of HIV supports the role of LLPs
as determinants of Env function, but reveals for the first time the influence of virus strain on LLP mutant phenotypes.
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biosynthesisIntroduction
The envelope protein of the HIVand SIV lentiviruses consist
of the surface unit (SU) gp120 and transmembrane (TM) gp41
proteins. The SU protein binds the host cellular CD4 receptor
and a chemokine coreceptor, while the TM protein mediates
fusion to permit virion entry into the cell (Hunter, 1997; Wyatt
and Sodroski, 1998). Compared to other member of the Re-
troviridae family, the TM of lentiviruses is distinguished by the
presence of a relatively long intracytoplasmic domain (ICD) of
about 150–200 amino acid residues. The Env ectodomains have
been the main focus as determinants of Env-related phenotypes,
especially with the availability of the crystal structures for these
protein sequences (Chan et al., 1997; Kwong et al., 2000;⁎ Corresponding author. Department of Molecular Genetics and Biochemistry,
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1999). Until relatively recently, the ICD segments of HIV and
SIV Env were believed to be dispensable, as truncation mutants
lacking ICD were found to replicate in cell culture (Chakrabarti
et al., 1989; Hirsch et al., 1989; Kodama et al., 1989; Wilk et al.,
1992). In contrast, other early in vitro studies of the HIV ICD
indicated that the ICD is indeed important to Env function
(Dubay et al., 1992; Gabuzda et al., 1992; Yu et al., 1993), but
these latter reports gained little attention.
Over the last decade, however, numerous studies have
identified the ICD as a critical determinant of Env function and
structure, including the role of Env in viral replication,
infectivity, cytopathicity, pathogenicity, and immunogenicity,
thus providing compelling evidence for the importance of the
ICD in Env structure and function in vitro and in vivo (Blot
et al., 2003; Bultmann et al., 2001; Day et al., 2004; Edwards
et al., 2002; Egan et al., 1996; Luciw et al., 1998; Wyss et al.,
2005; Ye et al., 2004). For example, several studies have
reported a critical role for the HIV ICD in virion assembly by
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with the observation that mutations in the MA region that result
in defects in Env incorporation or virus infectivity can be
restored by compensatory mutations in the gp41 ICD (Freed and
Martin, 1995, 1996; Mammano et al., 1995; West et al., 2002).
Another report demonstrated that mutations in the gp41 ICD
that disrupt Env incorporation can be reversed by mutations in
the MA gene (Murakami and Freed, 2000a). Recent studies also
indicate that Gag processing and Env interactions are coupled to
control the fusion activity of Env to prevent infection by
immature virus particles and that the down-regulation of Gag by
the ICD is likely an important regulatory step during virus
assembly and budding (Chan and Chen, 2006; Murakami et al.,
2004; Wyma et al., 2000, 2004).
In addition to ICD interaction with Gag, the ICD of HIVand
SIV have been shown to play a role in Env neutralization
sensitivity (Edwards et al., 2001, 2002; Kalia et al., 2005;
Vzorov et al., 2005; Ye et al., 2004; Yuste et al., 2005). For
example, the truncation of the HIV ICD has been shown to
increase the neutralization sensitivity of the Env protein,
evidently by exposing neutralizing epitopes that are in full-
length Env sequestered from antibody recognition, suggesting
an important role for the ICD in immune evasion in vivo
(Edwards et al., 2001, 2002). Other studies have demonstrated
that the ICD of HIV or SIV is an important determinant of Env
incorporation into virions and that changes within the ICD can
have an effect on the stability of the gp120–gp41 complex
(Affranchino and Gonzalez, 2006; Akari et al., 2000; Celma et
al., 2001; Kalia et al., 2003; Lee et al., 2002; Manrique et al.,
2001; Murakami and Freed, 2000b; Piller et al., 2000; Yuste et
al., 2004, 2005; Zingler and Littman, 1993). Supporting these in
vitro studies is the observation that the ICD is a critical locus of
attenuation of SIV during experimental infections of rhesus
macaques (Luciw et al., 1992; Marthas et al., 1989; Shacklett et
al., 2000, 2002). In addition, occasional reversions of stop
codons in the ICD and the resultant expression of full length
Env is associated with a rapid and marked increase in viral load
and progression to SAIDS (Luciw et al., 1998).
The ICD of HIValso contains a number of highly conserved
sequence motifs that likely play a role in its functional activities.
Two such sequences, YXXФ and dileucine, are characteristic of
protein endocytic and trafficking signals and may function in to
down regulate the cell surface exposure and immune recogni-
tion of Env (Boge et al., 1998; Egan et al., 1996; Ohno et al.,
1997; Rowell et al., 1995; Wyss et al., 2001; Ye et al., 2004). In
addition to the YXXФ and dileucine motifs, the ICD is
predicted to contain two highly positively charged amphipathic
α-helical segments, LLP-1 and LLP-2, that are linked by a
neutral leucine zipper-like motif (LLP-3) to form an extended
helical structure modeled to be closely associated with the lipid
bilayer (Eisenberg and Wesson, 1990; Hunter and Swanstrom,
1990; Kliger and Shai, 1997; Miller et al., 1991; Venable et al.,
1989). Recent investigations of the role of the ICD sequences in
HIV-1 infectivity and replication have demonstrated the
potential importance of these regions to the viral life cycle.
For example, certain positive to negative charge substitutions
within the LLP-1 sequence were shown to reduce viralinfectivity and Env incorporation (Kalia et al., 2003; Piller et
al., 2000). Other amino acid substitutions or deletions within
this same sequence also reduced Env incorporation and
infectivity, and in certain cases, targeted Env for degradation
(Lee et al., 2002). With regard to LLP-2, it was recently
demonstrated that truncation of the ICD within this region
resulted in an increase in cell-to-cell fusion suggesting a
mechanism by which the interaction of LLP-2 with the cellular
membrane serves to restrain the membrane disruptive potential
of Env (Wyss et al., 2005). Moreover, the region of the ICD
containing the LLP sequences is proposed to play a role in the
interaction between Env and the Gag protein and to affect Env
incorporation into virus particles (Celma et al., 2001; Cosson,
1996; Freed and Martin, 1996; Murakami and Freed, 2000a;
Piller et al., 2000). Within LLP-3, a diaromatic sequence was
shown to be responsible for the targeting of Env to the trans-
Golgi network and thus important for Env incorporation into
virions and infectivity (Blot et al., 2003; Lopez-Verges et al.,
2006).
In a recent report, positive to negative charge substitutions
were introduced into the LLP-1 (MX1, R846E and R848E) and
LLP-2 (MX2, R770E and R788E) regions of ME46, a dual
tropic primary isolate of HIV-1 (Kalia et al., 2003). The
rationale behind these substitutions is based on the observation
that truncations of the ICD can induce major conformational
alterations in Env and that amino acid substitutions may provide
a more specific modification to evaluate alterations in Env
function. Additionally, it has been demonstrated that specific
point mutations of arginine to glutamic acid residues can
substantially alter the membrane disrupting activities of the LLP
peptide sequences (Miller et al., 1993; Tencza et al., 1995).
Incorporation of the R846E and R848E mutations in the LLP-1
region of ME46 resulted in a virus that showed a substantial
decrease in infectivity, replication capacity, and Env incorpora-
tion, despite the fact that intracellular Env expression and
processing were normal. Similar point mutations made in the
LLP-2 of ME46 revealed a novel mutant that replicated to
parental levels and displayed parental levels of Env incorpora-
tion into virus particles. However, the mutant LLP-2 virus was
reduced in its ability to induce syncytia, and this phenotype was
directly correlated to a reduction in Env mediated cell-to-cell
fusion (Kalia et al., 2003). In a subsequent study, it was
demonstrated that changes within the LLP-2 region of ME46
could induce subtle, yet statistically significant alterations in the
conformation and neutralization sensitivity of both gp120 and
gp41, suggesting allosteric effects of the ICD on Env
conformation (Kalia et al., 2005).
In the current study, we introduced these LLP point muta-
tions alone or in combination in the context of a related, but
distinct primary dual-tropic isolate of HIV-1, 89.6, to determine
if homologous LLP mutations would confer phenotypes similar
to those observed with ME46. Our results demonstrate that the
LLP regions are critical, conserved structural motifs that play
vital roles in viral envelope function, and that minor alterations
within these motifs can produce profound changes in viral
phenotypes. However, the effects of some of these LLP
mutations differ between ME46 and 89.6, indicating that the
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mutations within a given specific viral envelope species.
Results
Rationale and construction of ME46 and 89.6 ICD mutants
The HIV-1 strains, ME46, and 89.6, are both dual tropic
clade B isolates that have been described previously (Chen et
al., 1997; Collman et al., 1992; Doranz et al., 1996). In a
previous study, a pair of arginine to glutamic acid residue
substitutions were introduced into the LLP-2 (770E/788E) and
LLP-1 (843E/845E) regions of ME46 based on the fact that
these positively charged residues are highly conserved, are
present on the hydrophilic face of the predicted amphipathic α-
helical structure of these peptide segments, and are important
for the membrane perturbing properties of the peptide
sequences (Kalia et al., 2003; Miller et al., 1993; Tencza et
al., 1995, 1999). In the context of proviral mutant clones, it has
been demonstrated that charge substitutions can influence Env
function (Kalia et al., 2003; Piller et al., 2000). For the currentFig. 1. HIV ICD Structure and positions of amino acid changes. (A) The linear sequ
(GenBank #AY669722), and 89.6 (GenBank #U39362) are shown starting with the t
the bottom is based on the HXB2 strain. The dashed lines in the ME46 and 89.6 se
followed by the membrane spanning domain (MSD) (Gallaher et al., 1989). Down
antibodies (Kennedy et al., 1986). Lentiviral lytic peptide (LLP) regions 1 and 2 h
membrane like environments and to have potent anti-microbial activities (Gawrisch
1999). A third region (LLP-3) also has anti-microbial activity and contains a leucin
made on the hydrophilic face of the LLP-2 and LLP-1 regions were introduced alone
position. (B) The mutations that were introduced alone or in combination into ME4
ME46 and 89.6 were located in the HXB2 reference strain using the HIV/SIV Sequen
content/hiv-db/LOCATE/locate.html) to determine the position of the mutations relati
and 89.6 are shown in the center and right hand columns, respectively. The amino acid
protein and the mutant amino acid residue. The HXB2 numbering in the left hand cstudy, the positions of the introduced mutations into ME46 and
89.6 relative to their positions in the HXB2 reference strain are
shown in Fig. 1A, and a summary of the panel of mutant viruses
bearing one or more of these mutations is outlined in Fig. 1B.
The ME46 virus that contains the 770E and 788E modifications
in LLP-2 represented a novel ICD mutant that displays similar
replication properties to the parental virus, but was shown to be
defective in cellular cytopathicity (Kalia et al., 2003). These
LLP-2 mutations were introduced alone or in combination into
89.6 (Fig. 1B). However, because 89.6 contains a leucine at
position 770 (Fig. 1A), a second double mutant, 772E/788E,
was constructed with both viruses to determine if the reduced
cytopathicity was dependent on the location of the glutamic acid
substitutions. Additionally, the 846E and 848E pair of
mutations was incorporated into 89.6 LLP-1 to asses the strain
specificity of the conferred phenotypes of these mutations that
resulted in a loss of ME46 replication competence and a defect
in Env incorporation (Kalia et al., 2003). The proviral DNA for
all six mutant viruses and both parental viruses were
individually transfected into 293T cells to produce virus stocks
for the assays described below.ences of gp41 from the HXB2 reference strain (GenBank #NC_001802), ME46
ryptophan-rich region (Trp-Rich Region). The amino acid residue numbering at
quences represent sequence identity with that of HXB2. The Trp-Rich region is
stream of this region is the Kennedy epitope that is recognized by neutralizing
ave been shown as peptides to assume an amphipathic α-helical structures in
et al., 1993; Miller et al., 1991, 1993; Srinivas et al., 1992; Tencza et al., 1997,
e-zipper like sequence (Kliger and Shai, 1997). The glutamic acid substitutions
or in combination into ME46 and 89.6, are indicated by an arrow and the residue
6 and 89.6 are summarized in the table. The LLP-2 and LLP-1 sequences from
ce Locator Tool at the Los Alamos Sequence Database (http://www.hiv.lanl.gov/
ve to HXB2 (left hand column). Strain specific numbering and changes for ME46
carried by the parental virus is indicated first, followed by its position in the Env
olumn is used throughout the rest of the text.
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To determine if the introduced mutations had an effect on
viral infectivity in a single round of replication, TZM-bl
indicator cells were infected in parallel with either the
parental virus or one of the mutant derivatives, and 48 h post-
infection, β-galactosidase activity was assayed as described in
Materials and methods. The average light intensity units
(LIU) for each mutant derivative are expressed as percent
relative infectivity compared to the parental virus (Fig. 2). For
both virus strains, the combination of the LLP-1 846E and
848E mutations resulted in a defect in the ability of the
mutant viruses to infect TZM-bl cells (Fig. 2). In contrast,Fig. 2. Infectivity of HIVME46 and 89.6 mutant viruses as measured in TZM-bl
indicator cells. TZM-bl indicator cells, which are stably transduced to express
CD4, both co-receptors, and both luciferase and β-galactosidase (β-gal) genes
that are under control of the HIV-1 LTR (Derdeyn et al., 2000; Wei et al., 2002),
were infected with the indicated virus after p24 level normalization. After 48 h
post-infection, cells were lysed with the Beta-Glo Assay System reagent
(Promega, Madison, WI), and β-gal activity was measured using a Veritas
microplate luminometer. An average light intensity unit (LIU) for each mutant
was compared to the respective parental virus (relative infectivity) in three to
four independent experiments each done in quadruplicate. Error bars represent
the standard error of measurement (SEM). (A) Infectivity of ME46 mutant
viruses relative to the ME46 parental virus. (B) 89.6 mutant virus infectivity
relative to the 89.6 parental virus.differential infectivity phenotypes were observed between the
two viruses with the LLP-2 mutations. The 770E mutation
conferred a 2-fold reduction in infectivity in ME46 (Fig. 2A),
while the same mutation in 89.6 resulted in a virus that
demonstrated a greater than 2-fold increase in infectivity
compared to the parental virus (Fig. 2B). In ME46, a
reduction in infectivity conferred by the 788E mutation was
additive to that of the 770E mutation (770E/788E, Fig. 2A).
While the 788E mutation also showed a greater than 2-fold
reduction in mutant 89.6 infectivity, there was no additive
inhibition when combined with the additional 770E mutation
(Fig. 2B). Interestingly, the 772E and 788E mutations
individually resulted in 89.6 mutant derivatives that were
decreased in infectivity by 40–50%, but the mutant 89.6 virus
with both changes displayed parental levels of infectivity. In
contrast, the negative effect of the 788E mutation on ME46
infectivity was not reversed in combination with the 772E
mutation, despite the fact that the ME46 mutant derivative
with only the 772E mutation showed parental levels of
infectivity (Fig. 2A). These results demonstrate the differ-
ential effects of specific LLP-2 mutations in the two viral
strains on infectivity as measured in TZM-bl cells.
Differential replication competence of the LLP mutant
derivatives in the CEMX174 cell line and primary
human PBMC
The ability of the mutant derivatives to establish a
productive infection in the CEMX174 cell line and the more
biologically relevant human peripheral blood mononuclear
cells (PBMC) was determined. For both cell types, similar
amounts of virus based on the p24 content of the viral stocks
were used to infect the cells, and replication levels were
determined by measuring p24 production in the supernatant.
The ME46 and 89.6 viruses with both the 846E and 848E
LLP-1 mutations were not able establish a productive infection
in CEMX174 cells (data not shown). As with the single cycle
infectivity data, the LLP-2 mutations had differential effects on
the replication competence of the two strains. Three of the
LLP-2 ME46 mutant derivatives (770E, 788E, and 770E/
788E) replicated to parental levels in CEMX174 cells (Fig.
3A). The ME46 772E/788E mutant showed slightly delayed
replication kinetics, but the amount of virus produced by day
10 was near parental virus levels. Only the ME46 772E mutant
displayed a consistent average 2-fold reduction in replication
in CEMX174 cells compared to parental ME46 on days 6, 8,
and 10. In contrast, the various 89.6 LLP-2 mutants displayed
a broader range of replication kinetics compared to the parental
virus. At one end of the spectrum, the double 772E/788E
mutant 89.6 virus was replication defective in CEMX174 cells
(Fig. 3B). In the middle of the spectrum, the 772E, the 788E,
and 770E/788E mutations in 89.6 LLP-2 resulted in viruses
with delayed and reduced replication kinetics relative to the
parental 89.6 virus (Fig. 3B). At the other end of the spectrum,
the 770E mutation in 89.6 appeared to increase the peak levels
of virus replication by about 30% relative to the parental virus
at their respective peaks of virus production in the CEMX174
Fig. 3. Replication kinetics in the CEMX174 cell line and human PBMC. CEMX174 cells or human PBMC were infected with each of the indicated viruses that were
normalized to p24 levels, and the respective cultures were maintained as described Materials and methods. At periodic intervals, viral supernatants were harvested, and
the level of p24 production was determined using a p24 ELISA kit. (A and B) Replication kinetics of ME46 and 89.6 and mutant derivative viruses in CEMX174 cells,
respectively. (C and D) Replication kinetics of ME46 and 89.6 and mutant derivative viruses in human PBMC, respectively. The replication kinetics for each virus is
identified by the legend to the right of each graph. The graphs are representative of at least two independent experiments.
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2–3 independent assays.
With human PBMC, it was observed that ME46 and 89.6
viruses with the combination of the LLP-1 846E and 848E were
unable to establish a productive infection, in agreement with the
results from CEMX174 cells (Kalia et al., 2003, data not
shown). In contrast, the mutant LLP-2 ME46 and 89.6 viruses
were all replication competent in PBMC. With the ME46 LLP2
mutants, the 772E, 770E/778E, and 772E/788E mutants
reduced the apparent peak levels of virus production relative
to parental ME46 by approximately 20–40%, while the
remaining LLP-2 mutants displayed replication levels similar
to parental ME46. All of the 89.6 LLP-2 mutant viruses
displayed virtually identical replication kinetics and levels
compared to parental 89.6, with only the 770E/788E mutant
displaying virus production that was about 25% above that
observed with the parental 89.6 virus. Taken together, these
results indicated that both cell type and Env specificity can have
a differential effect on the observed replication phenotype for
the LLP-2 mutants, in contrast to the consistent effect of LLP-1
mutations.Cell-to-cell fusion mediated by 89.6 and ME46 LLP-2 Env
mutant proteins
Based on our previous observations of LLP-2 mutations
affecting viral syncytium formation and fusion activity (Kalia et
al., 2003), a quantitative luciferase based cell-to-cell fusion
assay was used to independently measure the fusion properties
of Env apart from viral replication and the other viral proteins
(Edwards et al., 2002; Rucker et al., 1997). For this assay, 293T
effector cells expressing the test Env protein were mixed with
QT6 target cells expressing the CD4 receptor and the CXCR4
co-receptor. Syncytium formation was allowed overnight, and
on the following day, luciferase activity was measured from the
cell lysate. The results of these assays demonstrated that most of
the LLP-2 mutations in ME46 reduced the fusogenicity of the
Env protein relative to the parental viral Env (Fig. 4A). ME46
Env proteins with a single mutation (770E, 772E, or 788E) were
reduced in fusogenicity by about 20–50% compared to parental
Env, while Env proteins with double mutations (770E/788E and
772E/788E) were reduced in fusogenicity by more than 70%
compared to the parental Env fusogenic activity, suggesting an
Fig. 4. Cell-to-cell fusion mediated by parental and mutant envelope proteins.
The env sequence was cloned from proviral DNA from each of the viruses
into the mammalian expression vector pTR600 (Ross et al., 2000, 2001).
Cell-to-cell HIV Env mediated fusion was performed and assayed as
described in Materials and methods and elsewhere (Edwards et al., 2002;
Rucker et al., 1997). (A) Relative cell-to-cell Env mediated fusogenicity of
ME46 Envs bearing the indicated mutations compared to the parental Env
protein. (B) The ability of 89.6 Envs containing the indicated mutation to
promote cell-to-cell fusion relative to the 89.6 parental envelope. The data is
a result of an average of 3 to 6 independent experiments each done in
quadruplicate, and the error bars represent the SEM.
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reduction in fusogenicity observed with the individual 770E and
772E LLP-2 mutations in ME46 Env, the individual 770E and
772E mutations in the 89.6 LLP-2 region failed to decrease the
fusogenicity of the 89.6 Env in the standard assay (Fig. 4B). The
89.6 Env with the 788E mutation was about 50% reduced in
fusogenic activity relative to the parental Env, but the addition
of the 770E mutation did not further decrease Env fusogenicity,
the latter being in contrast to the additive effect observed with
the ME46 Env with the same mutations. The 89.6 Env with the
772E/788E mutations was similar to the homologous ME46
mutant Env in that both were reduced by about 70% in
fusogenic activity compared to their respective parental Env.
These fusogenicity assays, in agreement with the previous
single cycle infectivity assays, demonstrated the role of LLP-2
as a determinant of Env fusogenicity, but highlight the potential
for differential effects on this Env property caused by identical
mutations in the two Env species.Env incorporation into virus particles and total Env expression
from cellular lysate
Previous studies from our lab with ME46 viruses indicated
that the double point mutation in LLP-1 resulted in a defect in
Env incorporation into virus particles, while the double point
mutation in LLP-2 did not affect Env incorporation (Kalia et al.,
2003). In agreement with the prior report with the ME46 LLP-1
mutant virus (Kalia et al., 2003), an 89.6 mutant virus with the
846E and 848E modifications showed a nearly 8-fold decrease
in Env incorporation compared to the parental virus (data not
shown). In light of observed alteration in viral infectivity and
replication properties observed with various LLP-2 mutants, we
sought to determine the effects of the various mutations on the
LLP-2 mutant Env expression in cells (Figs. 5A and B) and
incorporation into viral particles (Figs. 5C and D). Mutant
proviral clones containing the various LLP mutations were
transfected into 293T cells, and the cellular lysates and
supernatants from the same transfection were assayed by
immunoblots for Env expression or incorporation, respectively.
The data presented in Fig. 5 demonstrated that the LLP-2
mutations in ME46 Env did not substantially affect either the
levels of Env expression (Fig. 5A) or incorporation into virus
particles compared to the parental virus (Fig. 5B). Densitometry
analysis of blots from two to three independent experiments
indicated a less than 1.5-fold increase in Env incorporation for
ME46 772E mutant viruses, as calculated from average gp41/
p24 ratios (Fig. 5E). As observed with LLP-2 mutants in ME46,
the LLP-2 mutations in 89.6 did not substantially affect the
levels of Env expression (Fig. 5C). However, the various LLP-2
mutations in 89.6 Env all resulted in an apparent increase in the
levels of Env incorporation with the 89.6 viruses (Fig. 5D).
Based on the densitometry results of blots from 2 to 3
independent experiments, the ratio of gp41 to p24 was increased
approximately 2- to 3-fold (Fig. 5F) in the 89.6 LLP-2 mutants
compared to the parental 89.6 virus.
Discussion
We and others have previously demonstrated by the
introduction of point mutations or deletion of short stretches
of amino acids that the LLP-1 and LLP-2 domains perform
critical, but distinct roles in HIV Env incorporation, replication
kinetics, infectivity, and/or fusogenicity (Kalia et al., 2003; Lee
et al., 2002; Murakami and Freed, 2000a; Piller et al., 2000).
However, these studies have all focused on the effects of LLP
mutations in the context of one particular strain of HIV. Since it
has been demonstrated that observed phenotypes conferred by
mutations within the ICD can be cell-type dependent (Akari et
al., 2000; Dubay et al., 1992; Gabuzda et al., 1992; Lambele et
al., 2007; Murakami and Freed, 2000b; Piller et al., 2000), the
current study was designed to determine whether or not
homologous mutations within the LLP regions of two different
strains of HIV would confer similar phenotypes. A summary of
these results is provided in Table 1. The data indicate that the
specific point mutations within the LLP-1 were consistent in
both viral strains in producing a defective Env phenotype that
Fig. 5. Envelope expression and processing, incorporation into virus particles, and densitometry analysis of Env incorporation. The data in this figure show the levels
of envelope expression, processing, and incorporation among the ME46 and 89.6 mutant and parental viruses. 293T cells were transfected with proviral DNA, and the
cell lysates and supernatants were harvested and processed for expression and incorporation analyses, respectively as described in Materials and methods. Panels A and
B show the level of Env expression and processing from the ME46 or 89.6 proviral constructs, respectively, while panels C and D display the levels of Env
incorporation from the same transfection shown in panels B and C. Numbers to the left of each film in panels C and D represent the mass in kilodaltons (KD) while the
viral proteins are identified on the right. The blots shown are representative of two to three independent transfections. For the graphs shown in panels E and F, X-ray
films from two to three independent transfections were subjected to densitometry using a Bio-Rad Gel Doc 2000 imagining system, and the amount of gp41 and p24
was determined for the mutants and the parental virus using Quality One 1D analysis software (Bio-Rad, Hercules, CA). The ratio of gp41 to p24 was then determined
for the ME46 and 89.6 viruses in panels E and F, respectively. The error bars represent the standard deviations.
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infectious and replication defective particles. In contrast, the
mutations in the LLP-2 domain were found to produce diverse
effects in the phenotypes of the two strains of HIV, as related to
Env incorporation, fusogenicity, and infectivity.
With both the ME46 and 89.6 strains of HIV-1, the
combination of the 846E and 848E mutations in LLP-1 had a
profound effect on viral infectivity and replication, apparently
correlating with the observed reduction of Env incorporation
into progeny virions (Kalia et al., 2003, Table 1). These two
targeted arginine residues within the LLP-1 region are highlyconserved, and the LLP-1 region shares sequence similarity
with other lentiviruses such as SIV and EIAV (Miller et al.,
1993; Tencza et al., 1997). This high degree of conservation in
LLP-1 suggests critical functions in HIV-1 replication. Piller et
al. (2000) introduced charged substitutions at positions 841 and
848 (RR/EE) into the NL4.3 strain of HIV-1. The mutant virus
produced from transfected 293T cells displayed about a 50%
reduction in Env incorporation, a 10-fold reduction in
replication activity in CEMX174 cells at the early time points,
and about a 5-fold reduction at the peak of viral replication
relative to the parental virus. In another study, Lee et al. (2002)
Table 1
Summary of the effects of LLP mutations on viral phenotypes relative to the parental virus
Mutation Infectivity a Replication in
CEMX174 b
Replication in
PBMCb
Fusion c Env Content d
ME46 89.6 ME46 89.6 ME46 89.6 ME46 89.6 ME46 89.6
846E/848E ↓ ↓ ↓↓ – ↓↓ e – NDf ND ↓ e ↓
770E ↓ ↑↑ = = = = ↓ = = ↑↑
772E = ↓ = ↓ = = ↓ = ↑ ↑↑
788E ↓ ↓ = ↓ = = = ↓ = ↑↑
770E/788E ↓ ↑↑ = ↓ = = ↓ ↓ = ↑↑
772E/788E ↓ = = ↓↓ = = ↓ ↓ ↑ ↑↑
a Infectivity as determined in TZM-bl cells (Fig. 2): “↓” indicatesN40% reduction relative to parental virus. “=”means infectivity was within 30% of parental virus.
“↑↑” indicates N100% increase in infectivity.
b Replication kinetics in CEMX174 cells and PMBC, respectively (Fig. 3). “–”sign indicates no detectable levels of p24 in the supernatant. “↓↓” shows N10 fold
reduction in replication kinetics. “↓” designates delayed or N two-fold reduction in replication activity. “=” signifies mutant viruses within 2 fold in the level of
replication relative of the parental virus.
c Cell-to-cell fusion mediated by mutant Env proteins (Fig. 4). “=” indicates mutant Env proteins within 20% the fusion activity of the parental Env. “↓” signifies a
decrease in fusion.
d The Env incorporation of the mutant LLP viruses (Figs. 5 and 6). “–” indicates a decrease in Env incorporation. “=” signifies equivalent Env incorporation levels.
“↑” designates mutant viruses with an increase in Env content. “↑↑” signifies a N two-fold increase.
e Data from Kalia et al. (2003).
f ND=not determined.
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residues within the LLP-1 domain could have an effect on Env
steady state expression, incorporation, or infectivity depending
on the specific mutation. Deletion of the last 12 residues of the
LLP-1 region has also been shown to reduce infectivity, and
other studies have indicated that these residues are important for
the transport of Env from the endoplasmic reticulum and the
overall association of this region with cellular membranes,
indicating an important function of LLP-1 for virus–host cell
interactions and Env transport (Chen et al., 2001; Yu et al.,
1993). Thus, these various studies consistently indicate an
important role for LLP-1 in Env function, and further studies are
certainly indicated to elucidate the mechanisms and cell
interactions by which LLP-1 contributes to HIV-1 infection
and replication.
In contrast to our results with the LLP-1 mutations, the LLP-
2 mutations resulted in strain specific phenotypic effects on
ME46 and 89.6. With regard to infectivity in the TZM-bl cell
line, homologous glutamic acid substitutions that conferred an
increase or decrease in infectivity in one virus did not
necessarily have the same effect in the other virus, highlighting
the importance of the specific Env species in modulating LLP-2
effects on function. In particular, 89.6 viruses with either the
770E mutation alone or a combination of both the 770E and
788E mutations had a greatly increased level of infectivity
compared to the parental virus, while these same modifications
in ME46 resulted in an additive decrease in infectivity (Fig. 2,
Table 1). Interestingly, the increase in infectivity observed with
the 89.6 LLP-2 mutants did not correlate with an evident
increase in replication levels in CEMX174 cells or in human
PBMC (Figs. 3B, D, and Table 1). Taken together, these
observations demonstrate the potential for strain-specific and
cell-specific effects of specific LLP-2 mutations, presumably
reflecting differences in the effects of overall Env sequences on
the structure and functional interactions of the envelope
complex with cellular proteins.We previously reported that an ME46 Env with both 770E
and 788E mutations was defective in the ability to promote cell-
to-cell fusion despite wild type expression levels of Env on the
cell surface (Kalia et al., 2003). However, the effects of
individual mutations on Env fusogenicity were not examined. In
the present study, we were able not only to characterize the
effect of the double LLP-2 mutation on 89.6 Env fusogenicity,
but also to analyze the relative contributions of the individual
point mutations to changes in fusogenicity for two Env species.
The results of these studies indicated that the double LLP-2
mutations also affected the ability of the 89.6 Env to promote
cell-to-cell fusion (Fig. 4, Table 1). In the case of the ME46 Env,
the single 770E mutation apparently contributed more to the
fusion defect than the 788E mutation alone; the opposite pattern
of single mutation effects on fusogenicity was evident for the
89.6 Env (Fig. 4). Additionally, Env proteins containing the
772E and 788E mutations were fusion defective, and again, the
788E mutation contributed more to this phenotype with the 89.6
Env than the 772E mutation alone. Both sets of observations
highlight the importance of the Env variant specificity in
determining the role of LLP-2 in fusion phenotypes. Other
recent studies have also indicated the importance of the LLP-2
sequence in the fusion process. For example, Wyss et al. (2005)
reported that Env proteins that retained the first four amino
acids of LLP-2 were normal for cell-to-cell fusion, but further
deletion increased fusion activity, presumably due to major
conformational changes in Env that exposed the CD4 binding
site and increasing the fusion potential of Env. In a previous
study, we showed that the 770E and 788E mutations together
did not increase exposure of either the CD4 or the co-receptor
binding sites (Kalia et al., 2005).
A prior report with ME46 indicated that the combination of
the 770E and 788E mutations did not alter the Env content in
virus particles or alter Env expression and processing (Kalia
et al., 2003), thus it was not surprising that these phenotypes were
not altered with viruses that possessed only one of these
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viruses that showed a modest increase in Env incorporation were
those bearing the 772E mutation. In contrast, all of the LLP-2
89.6 mutants had at least a 2- to 3-fold increase in the levels of
Env incorporation (Figs. 5B, 5F, and Table 1). This increased
incorporation could not be attributed to increased expression or
processing (Fig. 5D), so it is likely that the increased Env
incorporation occurs at some point during the assembly process.
Interestingly, increased levels of Env incorporation did not
necessarily increase other Env-related functions, such as
infectivity or replication kinetics. These findings with the 89.6
LLP-2 mutants are in contrast to reports with SIV where changes
in the ICD, even small deletions within LLP-2, can increase SIV
Env incorporation that can be correlated to increases in other
Env-related phenotypes (Celma et al., 2001; Manrique et al.,
2001; Yuste et al., 2004, 2005; Zingler and Littman, 1993). While
it is not known what the causes are for this difference, it is
possible that the Env content of the LLP-2 89.6 mutant viruses is
altered (i.e., reduced) during replication in permissive cells such
as CEMX174. Previous studies have shown that the Env content
of HIV virus particles can be altered in different cell types (Akari
et al., 2000; Murakami and Freed, 2000b; Piller et al., 2000).
Additionally, with a few exceptions, many of the prior reports
utilized truncated forms of the Env protein. The results of this
study clearly indicate that even single point mutations within the
LLP-2 region can alter Env incorporation, but the strain
specificity of this phenotype once again highlights the strain
dependence on the exact phenotypic alterations.
While the results of these and previous studies convincingly
establish a role for the ICD as a critical determinant of Env
conformation and function, the mechanisms by which the ICD
sequences, including LLP-1 and LLP-2, affect Env structural and
functional properties remain speculative at this time. Various
studies have demonstrated the importance of potential endocytic
motifs in the ICD as determinants of Env trafficking and surface
localization in infected or transfected cells (Boge et al., 1998;
Egan et al., 1996; Ohno et al., 1997; Rowell et al., 1995; Wyss et
al., 2001; Ye et al., 2004). Moreover, recent studies by others
have revealed a critical role for ICD–Gag interactions as a
regulator of Env fusogenicity (Murakami et al., 2004; Wyma et
al., 2004). We have previously proposed that that HIV-1 gp41
sequences including the membrane-proximal tryptophan-rich
domain, the membrane spanning domain, and the ICD
cooperatively facilitate Env association with the cellular and
viral lipid bilayers and that this series of helical peptide–
membrane interactions is a major determinant of Env fusogeni-
city, presumably via alterations in ectodomain conformations
(Kalia et al., 2003, 2005). Assuming the currently accepted
model that the ICD sequences are indeed all localized to the
interior surface of the lipid bilayer, the effects of LLP mutations
on Env functional properties would then be attributed to allosteric
effects on Env ectodomain conformation caused by changes in
the extent or stability of ICD-lipid bilayer interactions. In this
regard, we have previously shown that amino acid changes in
LLP sequences that reduce the characteristic positively charged
amphipathic potential of these peptide segments markedly reduce
membrane interactions (Miller et al., 1993; Tencza et al., 1995).The differential effects of identical LLP-2 point mutations on the
phenotypes of variant Envs may then be explained by the
influence of different Env sequences in determining the extent of
alterations in ICD-membrane interactions and resulting changes
in Env conformation caused by specific ICD mutations. The role
of membrane interactive peptide segments in modulating Env
structure and function is similar to that proposed for integrin
protein signaling in which conformational alterations in response
to extracellular or intracellular stimuli are produced by
cooperative allosteric interactions between ecto- and cytoplasmic
domains (Hynes, 2002).
It should be noted, however, that the model described above
for HIV-1 Env structure is based on the assumption that the gp41
protein contains a single membrane spanning domain and that
ICD sequences are indeed exclusively located on the interior side
of the lipid bilayer. While this membrane topology is widely
accepted, there are experimental data that indicate that segments
of the ICD may actually be located on the exterior of the lipid
bilayer. In early studies of Env neutralization determinants,
Kennedy and colleagues first reported that rabbit antiserum made
against a specific ICD synthetic peptide (“Kennedy epitope”)
located between the putative membrane spanning domain and
LLP-2 segments effectively neutralized infectious HIV-1 (Chanh
et al., 1986; Kennedy et al., 1986). More recently, Dimmock and
colleagues have published a series of studies that demonstrate
that peptide-specific antisera targeted to the Kennedy neutraliza-
tion epitope sequences are reactive with HIV-1 Env expressed on
the surface of cells or virus particles (Cheung et al., 2005;
Cleveland et al., 2003; Reading et al., 2003). Based on these
observations, these investigators have proposed an alternative
model for gp41 membrane topology that involves two additional
membrane spanning domains in the putative ICD preceding LLP-
2 in an arrangement that positions the Kennedy epitope on the
exterior of the lipid bilayer and the various LLP segments on the
interior surface of lipid bilayer (Hollier and Dimmock, 2005).
These investigators further suggest that gp41 may actually be in a
dynamic flux between the single or triple membrane spanning
domain structures. While further experiments are clearly needed
to definitively define the membrane topology of the ICD
sequences of gp41, it is interesting to note that both models
predict an exclusively internal location of the three different LLP
segments and thus are compatible with our model of the allosteric
effects of LLP on Env structure and function, as described above.
Materials and methods
Cells, proviral constructs, expression plasmids, antibodies, and
other reagents
Mammalian 293T (from M. Calos, University of Stanford
through T. Reinhart, University of Pittsburgh) and quail QT6 (a
kind gift from R.W. Doms, University of Pennsylvania, through
K. Stefano Cole, University of Pittsburgh) cells were maintained
in DMEM (Cambrex Bio ScienceWalkersville Inc., Walkersville,
MD) containing 10% fetal calf serum (FBS, Gemini Bio-
Products, Woodland, CA) and 2 mM L-glutamine (Invitrogen
Corporation, Carlsbad, CA). The TZM-bl indicator cell line
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the NIH AIDS Research and Reference Reagent Program, was
maintained in the same manner as above with the addition of 100
units/ml penicillin G and 100 μg/ml streptomycin sulfate (pen/
strep, Invitrogen Corporation, Carlsbad, CA). CEMX174 cells
(Salter et al., 1985) from the NIH AIDS Research Reagent
Program were grown in RPMI media (Cambrex Bio Science
Walkersville Inc., Walkersville, MD) supplemented with 10%
FBS, 2 mM L-glutamine, and pen/strep. Human peripheral blood
mononuclear cells (PBMC) were isolated from the buffy coat of
fresh human blood by Histoplaque-1077 (Sigma Diagnostics,
Inc, St. Louis, MO) density gradient centrifugation. The resulting
PBMC were maintained in the same media as CEMX174 cells
with the addition of 20% FBS and the M-form of phytohemag-
glutin (PHA, Invitrogen Corporation, Carlsbad, CA) at a starting
concentration of 1×106 cells/ml for 2–3 days prior to infection.
The HIV 89.6 full-length proviral construct (Collman et al.,
1992) was obtained from the NIH AIDS Research and Reference
Reagent Program, and the construction of the ME46 full-length
proviral DNA clone was described previously (Kalia et al., 2003).
The pTR600 expression plasmid, used to express the viral Env
proteins under control of the cytomegalovirus (CMV) promoter,
is a patented expression vector that was kindly provided by T.M.
Ross (University of Pittsburgh) (Ross et al., 2000, 2001). Plasmid
vectors used for the cell-to-cell fusion assay that express human
CD4 receptor, CXCR4 chemokine co-receptor, and the firefly
luciferase protein were also provided as a kind gift from R.W.
Doms through K. Stefano Cole, and their construction is
described elsewhere (Rucker et al., 1997). The recombinant
vaccinia virus, vTF1.1 (Alexander et al., 1992), also used for the
cell-to-cell fusion assay was provided by K. Stefano Cole.
Monoclonal antibodies 2F5 (Buchacher et al., 1994; Purtscher et
al., 1994, 1996) and AG 3.0 (Simm et al., 1995) used to detect the
gp41 and p24 viral proteins, respectively, on immumo-blots,
were acquired from the NIH AIDS Research and Reference
Reagent Program.Table 2
Nucleotide sequence of PCR primers used to introduce mutations
Primer name Sequence 5′→3′
ME46-3′ b GTTATTGGTCTTAAAGGTACCTGAGGT
ME46-5′b CAATATCGAGATCTTCAGACCTGGTGG
ME46-770E c CTCTTCAGCTACCACGAATTGAGAGA
ME46-772E AGCTACCACCGCTTGGAAGACTTACT
ME46-788E GAACTTCTGGGACGCGAGGGGTGGG
89.6-3′ d CAGACGGGCACACACTACTTGAAGCA
89.6-5′d GGCACTGAAGGAAATGACATAATCAC
89.6-770E CTCTTCCTCTACCACGAATTGAGAAA
89.6-772E TCTTCCTCTACCACCTCTTGGAAAAC
89.6-788E GAACTTCTGGGACGCGAGGGGTGGG
89.6-846E CTATTCGCAACATACCTACAGAGATCA
89.6-848E GCAACATACCTACAGAGATCGAGCA
a Relavant segments of the HIV-1 ME46 and HIV-1 89.6 env gene DNA sequen
Sequence Database to give the nucleotide positions relative to HXB2.
b ME46-3′ and ME46-5′ represent the non-mutagenic primers used in the overlap
c This table lists the sense strand mutagenic primer to pair with the 3′ non-mutage
appropriate corresponding anti-sense primer to pair with the 5′ non-mutagenic primer
represent the codon changed to introduce the glutamic acid residue mutation.
d 89.6-3′ and 89.6-5′ represent the non-mutagenic primers used in the overlap PCPCR mutagenesis and cloning
The construction of mutant ME46 proviral DNA constructs
bearing the 770E and 788E (ME46 MX2) or the 846E and 848E
(ME46 MX1) mutations are described elsewhere (Kalia et al.,
2003). In the current study, point mutations were introduced
into the LLP-1 and LLP-2 regions (Fig. 1 and Table 2) using a
modified overlap PCR mutagenesis protocol briefly described
elsewhere (Moeller et al., 2001). The nucleotide sequences of
the primers used for the PCR mutagenesis are listed in Table 2.
The Herculase Enhanced Polymerase Blend (Stratagene, La
Jolla, CA) was used for all PCR amplifications, and all
restriction enzymes used for cloning are from New England
Biolabs, Inc (Beverly, MA). For the construction of the
additional ME46 mutant proviral constructs, the full-length
proviral parental DNA was used as the template for PCR
amplification. In the first step of the overlapping PCR
mutagenesis, template DNA was combined with the 3′ non-
mutagenic primer (ME46-3′, Table 2) and one of the sense
mutagenic primers (ME46-770E, ME46-772E, or ME46-788E,
Table 2) in one reaction, while in a separate reaction, the 5′ non-
mutagenic primer (ME46-5′, Table 2) was combined with one
of the anti-sense mutagenic primers (sequences not shown). The
resulting PCR amplification products were purified using the
Qiagen Gel Extraction kit (Qiagen Sciences, Germantown, MD)
and were used as templates for the second step of the overlap
PCR mutagenesis. After 11 amplification cycles, the reaction
was paused, both non-mutagenic primers (ME46-3′ and ME46-
5′, Table 2) were added, and the PCR amplification was allowed
to continue for an additional 26 cycles. The PCR products from
the second step of the PCR mutagenesis were cloned back into
the full-length parental DNA using MfeI and XhoI restriction
sites that are unique within the ME46 construct. The ME46
proviral mutant construct with the 772E mutation was used as a
template for PCR mutagenesis to generate the mutant contain-
ing both the 772E and 788E mutations. All of the resultingNucleotide positions a
CTGACTG 9035–9002
AGGAGAT 7610–7646
CTTACTC 8517–8549
CTTGATTG 8523–8556
AAATCCTC 8571–8603
CTCA 9655–9626
ACTC 7443–7472
CTTACTC 8517–8549
TTACTCTTGATTGTA 8518–8558
AAGCCCTCAAATATTGG 8571–8612
GACAGGGCTTGGAAAG 8740–8782
GGGCTTGGAAAGGGCTTT 8746–8788
ces were entered into the HIV/SIV Sequence Locator Tool at the Los Alamos
PCR mutagenesis protocol.
nic primer for the first step of the overlap PCR mutagenesis in one reaction. An
was also used (sequence not shown) in a parallel reaction. The sequences in bold
R mutagenesis protocol.
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was PCR amplified by using a Perkin Elmer ABI 3100
sequencer (Perkin-Elmer Applied Biosystems, Warrington,
United Kingdom) to confirm that the clones did not contain
any additional missense mutations that might have been
introduced during the PCR amplification. For the construction
of the 89.6 proviral mutants, a subgenomic clone was made by
digestion of the full-length proviral DNAwith EcoRI and SphI.
This DNA fragment was inserted into the pUC19 cloning vector
(New England Biolabs Inc., Beverly, MA) and was used as a
template for the same PCR mutagenesis strategy described
above to generate sub-genomic clones containing one or more
of the mutations. These sub-genomic clones were verified by
sequencing the region that was PCR amplified. The clones were
digested with EcoRI and SphI, and the resulting fragments
containing the viral sequences were individually cloned back
into the full-length proviral DNA 89.6 parental clone digested
with the same enzymes. All of the full-length 89.6 proviral
mutant clones were verified by sequencing to ensure they still
had the intended mutation. For the generation of the Env
expression plasmids used for the cell-to-cell fusion assay, the
proviral DNAs were used as templates to PCR amplify the env
sequence using primers containing BamHI and HindIII restric-
tion sites for directional cloning into the pTR600 expression
vector (Ross et al., 2000, 2001).
Production of virus from proviral DNA
Viral Stocks of ME46, 89.6, and the mutant derivatives were
generated by transfecting 293T cells with the appropriate DNA
construct using the Lipofectamine 2000 transfection reagent
(Invitrogen Corporation, Carlsbad, CA). Briefly, 2 to 3 days
prior to transfection, T-75 cm2 flasks (BD Biosciences, Bedford,
MA) were seeded with 3×106 cells. Prior to transfection, the
89.6 constructs were digested with either SphI or FspI, and the
ME46 constructs were digested with NgoMIV. At 70–80%
confluency, the 293T cells were transfected with one of the
digested DNA constructs and Lipofectamine 2000 in the
presence of OptimemI with GlutaMax-I medium (Invitrogen
Corporation, Carlsbad, CA) according to the manufacturer's
protocol using a ratio of 1.7:1 Lipofectamine 2000 to DNA. At
2 days post-transfection, viral supernatants were harvested and
passed though 0.45 μm pore Millex Durapore membrane filters
(Millipore, Billerica, MA). The amount of virus produced from
transfected cells was determined by measuring p24 antigen
present in the supernatant using a p24 ELISA kit per the
manufacturer's protocol (DuPont, Wilmington, DE).
Infectivity assays using TZM-bl indicator cells
The single cycle infectivity of each of the mutant viruses
relative to the parental virus was determined in a single cycle
using TZM-bl indicator cells (Derdeyn et al., 2000; Wei et al.,
2002). One day prior to infection, TZM-bl cells were seeded in
96-well tissue culture plates (BD Biosciences, Bedford, MA) at
a concentration of 25,000–50,000 cells per well. The following
day, the culture media was removed, and filtered supernatantsfrom transfected 293T cells were used to infect the cells in
quadruplicate after p24 level normalization. After 2 h of
incubation at 37 °C, the infected wells were brought to 200 μl in
volume with DMEM containing 10% FBS, 2 mM L-glutamine,
and pen/strep. The cells were then washed 1× in phosphate
buffered saline (PBS) 48 h after incubation at 37 °C, and β-
galactosidase activity was measured using the Beta-Glo Assay
System (Promega, Madison, WI) by lysis of the cells with the
Beta-Glo Assay Substrate (Promega, Madison, WI). Following
a 1 hr incubation at room temperature, the lysed cells were
transferred to a 96-well white assay plate (Corning Inc.,
Corning, NY), and light intensity units (LIU) per well was
measured using a Veritas microplate luminometer (Turner
Biosystems, Sunnyvale, CA). An average LIU was determined
for each virus, and the average LIU of the mutant viruses was
compared to the appropriate parental virus. Each virus was
tested within each assay relative to the parental virus in three to
four independent experiments, and the standard error of
measurement (SEM) was determined for each mutant virus.
Viral replication kinetics
The replication kinetics of each mutant derivative virus was
compared to the parental virus in both the CEMX174 cell line
and in human PBMC. For kinetics in CEMX174 cells, cell-free
filtered supernatants from transfected 293T cells were normal-
ized to p24 levels (20 ng/ml) and used to infect 5×106 cells with
1 ml of virus for 1.5 h at 37 °C. The cells were then washed and
cultured in RPMI containing 10% FBS, 2 mM L-glutamine, and
pen/strep. At 1- to 3-day intervals, an aliquot of the supernatant
from each flask was removed prior to any media changes to
measure the amount of p24 antigen produced as described
above. After day 6, at 3- to 4-day intervals, half of the cell
culture and/or half of the cells were removed and replaced with
fresh medium. The kinetics of viral replication in human PBMC
was determined by the infection of 1×107 PHA stimulated
polybrene treated cells with 1 ml of cell-free filtered virus from
transfected 293T cells after p24 normalization (40 ng/ml). After
incubation for 1.5 h at 37 °C, the cells were washed twice with
RPMI containing 20% FBS, 2 mM L-glutamine, and pen/strep.
The infected cells were then resuspended at a concentration of
1×106 cells/ml per T-25 tissue culture flask with the culture
media mentioned above plus 10 units/ml of human IL-2 (Roche
Diagnostics, Indianapolis, IN). At intervals of 2–3 days,
supernatant was removed prior to any media changes to
determine the level of p24 antigen production. On days 3 and
10, one half of the culture media was replaced with fresh media,
and on day 7, half of the culture was replaced with fresh media
containing 5×106 PHA-stimulated PMBC.
Cell-to-cell fusion assay
A quantitative cell-to-cell fusion assay based on luciferase
activity was adapted from protocols described previously
(Edwards et al., 2002; Rucker et al., 1997). One day prior to
transfection, 293T cells were seeded at a concentration of
1×106 cells per well in 6-well plates (BD Biosciences, Bedford,
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1×105 cells per well in 24-well plates (BD Biosciences,
Bedford, MA). The following day, the 293T cells were
transfected as described above with one of the Env expression
plasmids using a Lipofectamine 2000 to DNA ratio of 1.7:1. In
parallel, QT6 (target) cells were transfected with CXCR4 and
CD4 expression plasmids under control of the CMV promoter
and a luciferase expression plasmid directed by the T7 promoter
(Rucker et al., 1997). After 4 to 6 h, the transfection mixture was
removed and replaced with DMEM containing 10% FBS and
2 mM L-glutamine. One day following transfection, the Env
expressing 293T (effector) cells were infected with a vaccinia
virus expressing T7 polymerase (Alexander et al., 1992) at a
multiplicity of infection of 10 in DMEM containing 2.5% FBS.
After 1 hr of incubation at 37 °C, the infection medium was
removed and replaced with DMEM containing 10% FBS, 2 mM
L-glutamine, and 100 μg/ml rifampicin (Sigma-Aldrich, St.
Louis, MO). The next day, the effector cells were mixed with
the target cells in DMEM containing 10% FBS, 2 mM L-
glutamine, 100 μg/ml rifampicin, and 10 mM cytosine
arabinoside (Sigma-Aldrich, St. Louis, MO). The effector and
target cells were allowed to fuse overnight, and the cells were
lysed with reporter lysis buffer (Promega, Madison, WI).
Luciferase activity was measured with the Luciferase Assay
System (Promega, Madison, WI), and LIU were measured using
a Veritas microplate luminometer (Turner Biosystems, Sunny-
vale, CA). Relative fusogenicity was determined by comparing
the LIU of each mutant envelope to the parental envelope, and
the resulting data is an average of 3 to 6 independent
experiments done in quadruplicate.
Viral protein analysis
To determine the levels of viral envelope incorporation into
virus particles, 293T cells in 6-well plates were transfected as
described above for the production of virus from proviral DNA.
Two to 3 days following the transfection, viral supernatants
were harvested, filtered, and measured for p24 levels as
described above. Similar amounts of virus based on the p24
ELISA of viral supernatants were centrifuged to pellet the virus,
and the resulting pellet was resuspended in PBS for sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis using 4–12% Bis-Tris NuPAGE gels with an
XCell SureLock Mini-cell apparatus and 1× MOPS buffer
(Invitrogen Corporation, Carlsbad, CA) according to the
manufacturer's recommendations. Following electrophoresis,
the proteins were transferred to polyvinylidine difluoride
(PVDF, Millipore, Billerica, MA) membranes using a Mini
Trans-Blot cell (Bio-Rad, Hercules, CA). Protein bands were
visualized by using the SuperSignal West Pico Chemilumines-
cent Substrate (Pierce Biotechnology, Rockford, IL) after
probing the appropriate area of the membrane with rabbit
polyclonal anti-gp120 (1:1000 dilution, Advanced Biotechnol-
ogies Incorporated, Columbia, MD), human anti-gp41 (2F5,
1:500 dilution), and mouse anti-p24 (AG 3.0, 1:250 dilution) as
primary antibodies followed by an appropriate secondary
antibody (Sigma-Aldrich, St. Louis, MO). The blots wereexposed to Kodak X-OMAT LS X-ray film (Eastman Kodak
Company, Rochester, NY), and the levels of gp41 and p24
proteins were measured from the X-ray film using a Bio-Rad
Gel Doc 2000 imaging system and Quality One analysis
software (Bio-Rad, Hercules, CA). For envelope expression and
processing, cells from the same experiment as the harvested
viral supernatant were lysed with 1× MOPS running buffer
(Invitrogen Corporation, Carlsbad, CA), subjected to one
freeze–thaw cycle, briefly sonicated with a Misonix Sonicator
3000 (Misonix, Farmingdale, NY), and subjected to SDS-PAGE
analysis and transfer to a PVDF membrane as described above.
Viral proteins gp120 and gp160 were visualized as described
above with the rabbit polyclonal anti-gp120 antibody as a
primary antibody followed by an appropriate secondary anti-
body (Sigma-Aldrich, St. Louis, MO).
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